W3 14 Anticoagulants and haemostasis Flashcards

1
Q

What does haemostasis mean?

A

The stopping of bleeding

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is coagulation?

A

The process by which blood turns to a solid

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What is different in injury that triggers haemostasis?

A

In injury blood RBCs and platelets come into contact with the sub-endothelium, which is rich with thrombotic and pro-aggregating proteins.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Briefly, what are the stages in haemostasis?

A

Primary haemostasis - vasoconstriction to limit blood loss and platelet activation leading to platelet block
Secondary haemostasis - activation of coagulation cascade to stabilise the block. Thrombin cleaves fibrinogen to fibrin, which is deposited to stabilise the clot.
To restore homeostasis, plasmin is activated to degrade the fibrin clot = fibrinolysis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What is a thrombus made from?

A

Platelets - haemostatic plug (primary haemostasis)
Coagulation - fibrin clot (secondary haemostasis)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

How do platelets usually circulate the blood?

A

In resting, non-activated form.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Platelet activation and inhibition is tightly regulated. Give some examples of platelet activators.

A

Collagen, thrombin, ADP, fibrinogen , VWF (leading to thrombosis)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Platelet activation and inhibition is tightly regulated. Give some examples of platelet inhibitors.

A

PGI2, NO (anti-thrombotic effect)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What are the stages of formation of a platelet plug?

A

Upon exposure of the sub-endothelium, platelets will interact with different receptors in the matrix, leading to rolling of platelets
This leads to their activation, and secretion of agonists from platelets, and their firm adhesion.
Will release molecules to recruit other platelets
Will aggregate through fibrinogen in the blood to form a platelet rich thrombus

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What on platelets becomes activated allowing them to aggregate?

A

Active integrin is able to bridge a fibrinogen molecule to form a platelet aggregate, adhere, and spread to support the coagulation cascade to stabilise the thrombi.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What are characteristics of a resting platelet?

A

Discoid shape
Granular
Integrins inactive

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What are the characteristics of activated platelets?

A

Shape change
Degranulation
Integrin activation
Aggregation, adhesion, spreading, procoagulant

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What agonists do platelets release after they’re activated?

A

ADP and TXA2, working in an autocrine way by binding on platelet receptors, to further activate platelets

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What substances are contained within the dense and a-granules of the platelet?

A

Dense granules - ADP, calcium, serotonin
a-granules - coagulation factors, anti-bacterial factors, chemo-attractants etc

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What happens in secondary haemostasis?

A

Coagulation. At the site of damage, thrombin is generated. It cleaves plasma fibrinogen to form a fibrin clot.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What are the functions of thrombin?

A

Induces vasoconstriction to limit blood loss
Leads to a fibrin clot
Leads to coagulation amplification
Leads to platelet activation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What is the different between the intrinsic and extrinsic coagulation pathways?

A

Extrinsic pathway - occur during tissue damage, leading to the exposure of tissue factor which can interact with factor 7a, and activate Xa
Intrinsic pathway - not activated easily at site of injury, more pathogenic activity eg during bacterial infection or stent implementation. Polyanion charges can activate factor 12.
Both converge with the generation of factor Xa - the key driver of the coagulation cascade.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What does factor Xa allow?

A

Allows the generation of thrombin (IIa) from prothrombin (II)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

There are 3 stages in thrombin formation for coagulation. What are they?

A

Initiation - due to exposure of tissue factor in the sub-endothelium, a small amount of thrombin is generated (not enough to form a fibrin clot)
Amplification - it activates other factors leading to more thrombin generation
Propagation - there is a burst of thrombin generation, crucial for fibrin formation and deposition

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

How is prothrombin turned to thrombin?

A

Prothrombinase complex is associated with the surface of platelets = Xa, calcium and Co-factor
It will traverse prothrombin (an inactive zymogen) into thrombin
Thrombin will cleave fibrinogen into fibrin to support clot generation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

How does thrombin positively and negatively feedback?

A

Thrombin positively feedbacks to activate other coagulation factors to amplify the coagulation cascade
Also has negative feedback loop, and when thrombin is generated it can bind to its receptor, thrombomodulin on endothelial cells, to activate protein C to inhibit the coagulation factors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

What 3 systems are there to limit/fight excess coagulation?

A

Tissue factor pathway inhibitor (TFPI) - limits tissue factor
Antithrombin - limits generation of thrombin
Activated protein C - activated by binding of thrombin to thrombomodulin, inhibits coagulation factors (Va and VIIIa)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

What is fibrinolysis?

A

The degradation of a fibrin clot.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

When is the fibrinolytic cascade activated?

A

Once coagulation is activated, and fibrin is deposited, to restore homeostasis, fibrinolytic cascade is activated.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

What is the aim of the fibrinolytic cascade?

A

To transform plasminogen into plasmin.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

What is the role of plasmin?

A

Plasmin will degrade the fibrin into fibrin-derived peptides, to inhibit the growth of the clot, to stabilise the vessel injury and prevent vascular occlusion.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

How is plasminogen turned to plasmin?

A

tPA (tissue plasminogen activator) and uPA (urokinase-type plasminogen activator) will activate plasminogen into plasmin, to degrade the fibrin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

What will thrombin do to fibrinolysis and how?

A

Thrombin will block fibrinolysis by activating TAFIa (thrombin-activatable fibrinolysis inhibitor). It can activate this by binding to thrombomodulin.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

What does coagulation ultimately lead to and what 3 pathways inhibit it?

A

Coagulation leads to thrombin generation and thus fibrin
Inhibited by - TFPI, AT, APC

30
Q

What does fibrinolysis ultimately lead to and what 3 pathways inhibit it?

A

Fibrinolysis leads to the degradation of fibrin
Inhibited by PAI-1, a2-anti plasmin, TAFIa

31
Q

What does TAFIa do?

A

TAFIa will inhibit lysis of the clot, inducing it’s stability. It reduces fibrin clot degradation.

32
Q

What is an anti-coagulant?

A

A drug that prevents blood from clotting (inhibits coagulation)

33
Q

What is an anti-thrombotic?

A

A drug that prevent thrombus formation (more general, eg antiplatelet, anticoagulant, fibrolytic agents)

34
Q

What is a thrombolytic drug (clot buster)?

A

A drug that dissolves blood clots

35
Q

What is the difference between the arterial system and venous system blood content/flow?

A

Arterial is a high shear system, with platelets critical
Venous is a low shear system, with coagulation critical

36
Q

What do the differences between the arterial and venous systems mean for their thrombi?

A

Arterial - forms white thrombi from predominantly platelets. Antiplatelet drugs (eg aspirin, clopidogrel)
Venous - forms red thrombi from predominantly red blood cells. Anti-coagulants (eg heparin, warfarin)

37
Q

What are the critical factors for thrombosis, giving examples for each?

A

Virchow’s triad:
Endothelial injury - eg trauma, atherosclerosis
Blood flow - eg immobile, atrial fibrillation
Hypercoagulation - eg inherited, pregnancy, medication

38
Q

What is a good thrombosis vs a bad thrombosis?

A

Good - stops bleeding, transient, non-occlusive
Bad - blocks blood supply, chronic, occlusive, embolise

39
Q

How does arterial thrombosis occur?

A

Under high stress, platelets roll on the exposed endothelium, get activated and secrete secondary mediators like ADP and TXA2, which work on autocrine pathway to activate platelets and recruit more platelets to the plug.

40
Q

What are the most classic classes of anti-platelet drugs?

A

COX inhibitors - eg aspirin
P2Y inhibitors - eg clopidogrel

41
Q

What are some other/more recent classes of anti platelets?

A

PAR1 inhibitors - the receptor of thrombin on platelets
Phosphodiesterase inhibitors - inhibit platelet activation
aIIbb3 inhibitors - inhibit aggregation of platelets

42
Q

Give 2 examples of aIIbb3 antagonists and why they’re no longer used much - not first choice.

A

Abciximab, Integrilin
Restricted to acute hospital care eg unstable angina
Associated with risk of excessive bleeding, stopped due to lack of efficacy and increased mortality

43
Q

Aspirin and clopidogrel are the first line choice antiplatelets. What do they do?

A

Aspirin - will inhibit COX, which inhibits TXA2 formation
Clopidogrel - will inhibit P2Y, so less ADP formation
Hence both inhibit the secondary mediator released by platelets, to inhibit the platelets activation and aggregation

44
Q

How does venous thrombosis occur?

A

Low shear stress in the venous system and turbulent shear due to the valves induces thrombi that are more rich in fibrin and red cells. Use anticoagulants to target this.

45
Q

What are the 4 classes of anticoagulants used?

A

Heparin (older)
Vitamin K antagonists
Direct thrombin inhibitors (more recent)
Factor Xa inhibitors (more recent)

46
Q

What are the actions of heparin?

A

Not a direct anticoagulant - it is a cofactor for antithrombin, binding to it, amplifying it’s effect so increases efficacy to inhibit thrombin, and inactivates the antithrombin-thrombin complex.
Heparin also inhibits lots of other activated coagulation factors

47
Q

What is warfarin?

A

A vitamin K antagonist

48
Q

What is the mechanism of action of warfarin/vitamin K antagonists?

A

Warfarin inhibits the carboxylation of inactive vitamin K dependent coagulation factors (eg 7, 9, 10 and prothrombin). These, if not carboxylated in the liver are not activated.
Thus it does not inhibit these factors directly, but inhibits vitamin K reductase which is important for the carboxylation for these factors.

49
Q

What commonly used clot busters are there?

A

Recombinant tOA
Urokinase
Streptokinase

50
Q

What do clot busters do?

A

Activate plasminogen, to lyse the thrombi (they don’t inhibit coagulation!)

51
Q

What are the types of haemorrhage?

A

Internal - leaky blood vessels inside body
External - natural opening or break in skin

52
Q

What are the causes of haemorrhage?

A

Trauma - different types of injury
Medical conditions:
- intravascular - defects in the blood
- intramural - defects in vessel wall
- extravascular - defects outside blood vessels

53
Q

Risk factors for haemorrhage

A

Congenital (eg haemophilia)
Medication (anticoagulants)
Age (poorly tolerate by elderly)
Trauma (burns, puncture, ballistic)
Disease (liver disease)
Infection (gastroenteritis)

54
Q

What can haemorrhagic shock cause?

A

Decreased blood volume - hypovolemia
Reduced cardiac output
Reduced organ perfusion

55
Q

What different types of haemorrhage are there (time wise)?

A

Primary - bleeding occurs during surgery
Reactionary - 2-3 hours after surgery
Secondary - bleeding occurs until 14 days after surgery, probably due to an infection post-surgery

56
Q

Complications of haemorrhage

A

Can range from soft tissue haematoma to severe blood loss

57
Q

How does the body physiologically and how do we clinically stop further blood loss due to haemorrhage?

A

Vasoconstriction (mechanically, naturally by vessels)
Haemostasis / thrombosis (haemostatic agents)
Fibrinolysis (antifibrinolytic agents)
Surgery

58
Q

How do we replace lost blood volume?

A

Volume expanders (crystalloids, colloids)
Blood transfusion

59
Q

What are crystalloids and colloids?

A

Crystalloids are aqueous solutions of mineral salts or other water soluble molecules
Colloids contain larger insoluble molecules, such as gelatin

60
Q

What haemostatic agents are there (to reduce bleeding)?

A

Recombinant factor VIIa (FVIIa)
Desmopressin (DDVAP)
Fibrinogen

61
Q

What is the role of the haemostatic agent recombinant factor VIIa?

A

Increases the formation of factors IXa and Xa
Increased thrombin generation and fibrin formation
Amplifies coagulation

62
Q

What is the role of the haemostatic agent desmopressin?

A

Vasopressin analogue
Stimulates release of VWF secretion from endothelial cells by acting on V2 receptor
Secondary increase in factor VIII levels
Increased fibrin formation and platelet deposition

63
Q

What is the role of the haemostatic agent fibrinogen?

A

Enhanced fibrin formation. Can inhibit fibrinolysis, inhibiting plasmin generation and limits fibrin degradation.

64
Q

What is the overarching role of haemostatic agents?

A

To amplify the coagulation cascade

65
Q

What antifibrinolytic agents are there and what do they do?

A

Tranexamic acid (TXA)
Epsilon aminocaproic acid (EACA)
Aprotinin (Trasylol)
They all inhibit conversion of plasminogen to plasmin and cause reduced fibrinolysis - increased clot stability

66
Q

What different topical haemostatic are used in dental surgery?

A

Gelatins, collagen and oxidised cellulose - reduce topical bleeding
Active agents - topical thrombin, direct fibrin sealants - to inhibit bleeding and reduce blood loss
Flowable agents - gelatin/collagen + thrombin, which will help reduce blood loss by increasing haemostasis

67
Q

What do you do in minor bleeds vs severe haemorrhage (for patients under anti-coagulants)?

A

Minor bleeding - gelatin along, fibrin glue and suture
Severe haemorrhage - cauterisation of soft tissue bleeding

68
Q

How do you deal with bleeding in patients under anti-coagulants?

A

HemCon dental dressing or HemCon bandage: achieve haemostasis within a minute and also fastens the wound healing. Positively charged dressing adheres to negatively charged RBC
Curettage technique at the site of extraction and then use either tranexamic acid, suture or gelatine sponge to control postoperative bleeding effectively.

69
Q

Why is it highly recommended to use haemostatic agents for patients under anticoagulants?

A

Because it is impossible to stop the anticoagulants, since they are at risk of thrombosis in these cases

70
Q

Local interventions - surgical and non-surgical haemostatic measures

A

Surgical intervention involves suturing the extraction or bleeding site
Non-surgical measures: sealants, adhesives absorbable agents, biologics combination products
Combination of both eg: tranexamic acid mouth wash along with gelatine sponge and sutures etc

71
Q

What systemic interventions might need to occur if patients have a systemic cause for bleeding?

A
  • administration of fresh frozen plasma (FFP) or both
  • factor replacement therapy using recombinant or plasma-derived anti-haemophilic factor A or anti-haemophilic factor B of VWF
  • intranasal desmopressin
  • oral or intravenous tranexamic acid
  • intravenous epsilon amino-d-caloric acid
72
Q

Why can’t you ask patients on anticoagulants to stop their treatment?

A

Risk of stroke or heart attack